Bath ASU’s full-time research and development laboratory does valuable work to improve the safety and stability of patient-bound products.
Our experts discuss research into the stability and use of monoclonal antibodies and antibody drug conjugates. Articles are assessed by our team based on the NHS Pharmaceutical Quality Assurance Committee’s Standard Protocol for Deriving and Assessment of Stability.
- M. Paul, V. Vieillard, E. Roumi, A. Cauvin, M.C. Despiau, A. Astier, 2012. Long-term stability of bevacizumab repacked in 1 mL polypropylene syringes for intravitreal administration. Annales Pharmaceutiques Françaises, 70, pp.139–154.
- M. Paul, V. Vieillard, E. Jaccoulet, A. Astier, 2012. Long-term stability of diluted solutions of the monoclonal antibody rituximab. International Journal of Pharmaceutics, 436, pp.282–290.
- M. Paul, V. Vieillard, R. Da Silva Lemos, L. Escalup, A. Astier, 2013. Long-term physicochemical stability of diluted trastuzumab. International Journal of Pharmaceutics, 448, pp.101–104.
- J. Kaiser, I. Krӓmer, 2011. Physicochemical stability of diluted Trastuzumab infusion solutions in polypropylene infusion bags. International Journal of Pharmaceutical Compounding, 15, pp.515–520.